Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer

doi:10.4251/wjgo.v10.i11.421

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8090)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

487

WORD

291

HTML

4472

Figures (1-2)

266

Tables (1-4)

239

Sum=5755

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1029

Download

1306

Sum=2335

Nov 15, 2018 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Nov 15, 2018; 10(11): 421-430
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.421

Table 3 Response evaluation n (%)

	sFOLFIRINOX	mFOLFIRINOX	P value
	(n = 88)	(n = 42)	P value
CR	1 (1.1)	1 (2.4)
PR	34 (38.6)	14 (33.3)
SD	36 (40.9)	20 (47.6)
PD	17 (19.3)	7 (16.7)
Objective response^a	35 (39.8)	15 (35.7)	0.656
Disease control^b	71 (80.7)	35 (83.3)	0.716

^aObjective response includes CR and PR;

^bDisease control includes CR, PR, and SD. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Citation: Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430
URL: https://www.wjgnet.com/1948-5204/full/v10/i11/421.htm
DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.421